Webster K. Cavenee
|Year of election:||2012|
|Section:||Human Genetics and Molecular Medicine|
|City:||La Jolla, CA|
CV Webster Cavenee - English (PDF)
Search among the members of the Leopoldina for experts in specific fields or research topics. After entering a name in the "Name" field, click on "Search" to go directly to a member profile. With the input and selection in the fields "City" and „Country", you can limit your search locally or regionally, or target specific sections of the Leopoldina. Alternatively or in combination a full-text search is possible for all member profiles - use the upper input field. The use of operators like AND, NOT or * is permitted in the full-text search. For example, you may search for "genetics" or "*genet*" to get results with "genetic" or "molecular genetics". For a new search please click on the following link or use the full-text search in the right column.
Main areas of research: Genetic cancer research, oncology, brain tumours, tumour suppression, glioblastoma
Webster K. Cavenee is a US American pioneer of genetic cancer research. He provided the first indisputable evidence for the existence of a gene that was responsible for the suppression of tumours, a so-called Tumour Suppressor Gene.
Already as a postgraduate student Webster Cavenee was able to bring about an extraordinary breakthrough by producing the first indisputable evidence of the existence of a so-called Tumour Suppressor Gene. These genes normally control the cell cycle and programmed cell death by means of specific proteins. A mutation of one such gene increases the probability of a tumour forming and the onset of cancer.
Cavenee’s further research work is closely linked to the US American Ludwig Institute for Cancer Research. As a professor and Director of the Ludwig Institute in San Diego he focussed his research on a particularly aggressive type of brain tumour in adults: the glioblastome, which is thus far considered incurable. Webster Cavenee described the formation, function and attributes of an important growth factor receptor, the mutated form of which fosters the development of such tumours. A team led by him developed an antibody against the mutated receptor and that has developed into a promising therapy against glioblastoma.
Cavenee ended his role as the Director of the Institute in 2015 but continues his scientific work. He since coordinates an international research alliance that consists of about 130 clinical researchers and basic researchers from the USA, China, Australia and Europe. The goal of the alliance is to promote and advance new clinical testing methods for the purpose of developing therapies against glioblastoma.
06108 Halle (Saale)
|Phone||0345 - 47 239 - 122|
|Fax||0345 - 47 239 - 139|